ANXA3 and breast carcinoma: For example, in vitro investigations on breast cancer cell lines HCC-1954 and MDA-MB-231 demonstrated that ANXA3 silencing using siRNA significantly reduced the expression of CDK4 and enhanced the expression of E2F1 and p27Kip1 (Kim et al., 2018).